文献速递间质性肺疾病

Admilparant(LPA1拮抗剂)治疗肺纤维化的2期随机临床试验

Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2025-01-01

这项2期随机双盲安慰剂对照试验在IPF和PPF平行队列中评估口服LPA1拮抗剂admilparant的疗效与安全性,患者每日两次接受30mg、60mg或安慰剂治疗26周。60mg admilparant组FVC下降较安慰剂减缓,PPF队列治疗差异有统计学意义,药物安全可耐受,支持开展3期试验。

要点

  • 60mg admilparant可减缓IPF和PPF患者26周FVC下降
  • PPF队列60mg组与安慰剂差异有统计学意义
  • 不良事件导致的停药率在admilparant组不高于安慰剂

核心结论

  • 60mg admilparant减缓肺功能下降且安全耐受,支持进一步3期评估。

研究设计与样本

  • 2期随机双盲安慰剂对照试验,IPF队列随机278例、治疗276例,PPF队列随机125例、治疗123例。
  • 患者按1:1:1接受30mg admilparant、60mg admilparant或安慰剂每日两次,治疗26周。
  • 允许背景抗纤维化治疗(两队列)和免疫抑制治疗(仅PPF)。

主要发现

  • IPF队列26周预测FVC百分比变化率:安慰剂-2.7%、30mg组-2.8%、60mg组-1.2%。
  • PPF队列26周预测FVC百分比变化率:安慰剂-4.3%、30mg组-2.9%、60mg组-1.1%。
  • 60mg admilparant与安慰剂治疗差异:IPF为1.4%(95%CI -0.1至3.0),PPF为3.2%(95%CI 0.7至5.7)。
  • 两队列中有或无背景抗纤维化治疗均观察到治疗效果。
  • 腹泻发生率在admilparant组与安慰剂组相似;所有组均见第1天给药后短暂血压下降,admilparant组更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) have high morbidity and mortality; thus, novel treatments are needed. Objectives: Assess efficacy and safety of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with IPF and PPF. Methods: This phase 2, randomized, double-blind, placebo-controlled trial included parallel cohorts of patients with IPF (n = 278 randomized, n = 276 treated) or PPF (n = 125 randomized, n = 123 treated) who received 30 mg of admilparant, 60 mg of admilparant, or placebo (1:1:1) twice daily for 26 weeks. Background antifibrotics (both cohorts) and immunosuppressants (PPF only) were permitted. Measurements and Main Results: Rates of change in percentage of predicted FVC over 26 weeks for IPF were -2.7% (placebo), -2.8% (30 mg), and -1.2% (60 mg) and for PPF were -4.3% (placebo), -2.9% (30 mg), and -1.1% (60 mg). Treatment differences between 60-mg admilparant and placebo were 1.4% (95% confidence interval, -0.1 to 3.0) for IPF and 3.2% (95% confidence interval, 0.7 to 5.7) for PPF. Treatment effect was observed with or without background antifibrotics in both cohorts. Diarrhea occurred at similar frequencies in admilparant arms versus placebo. Transient Day 1 postdose blood pressure reductions were observed in all arms in both cohorts but were greater with admilparant. Treatment discontinuations because of adverse events were similar across IPF arms and lower with admilparant (2.5% [30 mg]; 0% [60 mg]) versus placebo (17.1%) for PPF. Conclusions: In this first phase 2 study to evaluate antifibrotic treatment in parallel IPF and PPF cohorts, 60-mg admilparant slowed lung function decline and was safe and well tolerated, supporting further evaluation in phase 3 trials. Clinical trial registered with clinicaltrials.gov identifier (NCT04308681).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Corte TJ, Behr J, Cottin V, et al. Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. Am J Respir Crit Care Med. 2025. PMID: 39393084. doi:10.1164/rccm.202405-0977OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。